

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

**DATE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of Genscript Biotech Corporation (the “**Company**”) hereby announces that a meeting of the Board will be held on Friday, 25 March 2016, for the purposes of considering and approving the annual results of the Company and its subsidiaries for the year ended 31 December 2015 and its publication, considering the recommendation on the payment of a final dividend, if any, and transaction of any other businesses including considering the matters in relation to the exercise of share options granted/to be granted to the grantees under the Share Option Scheme adopted on 15 July 2015 and the Post-IPO Share Option Scheme adopted on 7 December 2015, details of the said Share Option Scheme and Post-IPO Share Option Scheme as disclosed in the prospectus dated 17 December 2015 of the Company.

By order of the Board  
**Genscript Biotech Corporation**  
**Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Nanjing, People’s Republic of China  
15 March 2016

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.*

\* For identification purposes only